| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/17/2001 | EP1068182A1 Process for preparing a protected 4-aminomethyl-pyrrolidin-3-one |
| 01/17/2001 | EP1068180A1 Process for alkylating hindered sulfonamides useful in the production of matrix metalloprotenase inhibitors |
| 01/17/2001 | EP1068178A1 NON-PEPTIDE GnRH AGENTS |
| 01/17/2001 | EP1068172A1 PLATELET AGGREGATION INHIBITION USING LOW MOLECULAR WEIGHT HEPARIN IN COMBINATION WITH A GP IIb/IIIa ANTAGONIST |
| 01/17/2001 | EP1067972A1 Multicomponent complex for use with a substrate |
| 01/17/2001 | EP1067967A1 A drug composition containing sodium pravastatin |
| 01/17/2001 | EP1067966A1 OPHTHALMIC COMPOSITION COMPRISING A $g(b)-BLOCKER |
| 01/17/2001 | EP1067965A1 Pharmaceutical composition for treating cerebral apoplexy and craniocerebral trauma |
| 01/17/2001 | EP1067960A2 A method of inducing an anti-tumor response against a lung metastasis in a melanoma patient |
| 01/17/2001 | EP1067958A2 Treatment of cardiac hypertrophy |
| 01/17/2001 | EP1067956A2 Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| 01/17/2001 | EP1067953A1 Methods for treating an ischemic disorder and improving stroke outcome |
| 01/17/2001 | EP1067942A1 High-energy cyclodextrin complexes |
| 01/17/2001 | EP1067941A1 Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate |
| 01/17/2001 | EP1067940A1 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 01/17/2001 | EP1067939A1 Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways |
| 01/17/2001 | EP1067938A1 Voacamine as anti-malarial agent and anti-malarial agent containing voacamine |
| 01/17/2001 | EP1067937A1 Sustained-release composition containing cefaclor |
| 01/17/2001 | EP1067936A1 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
| 01/17/2001 | EP1067935A1 Acylbenzoxazines for enhancing synaptic response(s) |
| 01/17/2001 | EP1067934A1 Oral liquid antidepressant solution |
| 01/17/2001 | EP1067933A1 Semi-synthetic ecteinascidins |
| 01/17/2001 | EP1067932A1 Methods for inhibiting mrp1 |
| 01/17/2001 | EP1067931A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | EP1067930A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | EP1067929A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | EP1067928A1 Methods for inhibiting mrp1 |
| 01/17/2001 | EP1067927A1 Antioxidant stabilizer system for pharmaceutical formulations |
| 01/17/2001 | EP1067926A2 Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cyclosporins |
| 01/17/2001 | EP1067925A1 Antidiabetic agents |
| 01/17/2001 | EP1067924A1 Use of a porphyrin for producing a medicine reducing the number of eosinophils |
| 01/17/2001 | EP1067922A1 Agents and methods for modulation of zinc transfer by metallothionein |
| 01/17/2001 | EP1067920A1 Methods and compositions for reducing uv-induced inhibition of collagen synthesis in human skin |
| 01/17/2001 | EP1067919A1 Dfmo and sulindac combination in cancer chemoprevention |
| 01/17/2001 | EP1067918A1 Stable dosage forms of fluoxetine and its enantiomers |
| 01/17/2001 | EP1067917A2 Method of treating dopaminergic and gaba-nergic disorders |
| 01/17/2001 | EP1067916A2 Method for producing transdermal therapeutic systems by using basic alkali metal salts for converting active agent salts into free bases |
| 01/17/2001 | EP1067915A2 Device for the transdermal delivery of diclofenac |
| 01/17/2001 | EP1067909A1 Cationic lipid formulation delivering nucleic acid to peritoneal tumors |
| 01/17/2001 | EP1067908A1 Anticancer compositions |
| 01/17/2001 | EP1067906A1 Maximizing effectiveness of substances used to improve health and well being |
| 01/17/2001 | EP1067905A1 Fizzy formulations |
| 01/17/2001 | EP1067904A1 Solid, quick dissolving cetirizine formulations |
| 01/17/2001 | EP1067903A1 Improved crystal structure |
| 01/17/2001 | EP1067897A1 An acidified composition for topical treatment of nail and skin conditions |
| 01/17/2001 | EP1067896A4 Ascorbyl-phosphoryl-cholesterol |
| 01/17/2001 | EP1067896A1 Ascorbyl-phosphoryl-cholesterol |
| 01/17/2001 | EP1067894A2 Protease inhibitors |
| 01/17/2001 | EP1067839A1 Pulmonary and nasal delivery of raloxifene |
| 01/17/2001 | EP1067838A1 Treatment of respiratory disease and otitis media |
| 01/17/2001 | EP1003501A4 Means of ascertaining an individual's risk profile for atherosclerotic disease |
| 01/17/2001 | EP0983258A4 N-hydroxy 4-sulfonyl butanamide compounds |
| 01/17/2001 | EP0808325B1 Androstane and pregnane series for allosteric modulation of gaba receptor |
| 01/17/2001 | EP0790998B1 Azo derivatives of 5-aminosalicylic acid for treatment of inflammatory bowel disease |
| 01/17/2001 | EP0786991B1 Polyamine compounds for treating vascular proliferative disorders |
| 01/17/2001 | EP0784475B1 Prostagladin analogues by the oral or vaginal route for the routine management of the third stage of labour |
| 01/17/2001 | EP0748191A4 Methods and formulations for use in treating oophorectomized women |
| 01/17/2001 | EP0730590B1 isoxazoline and isoxazole fibrinogen receptor antagonists |
| 01/17/2001 | EP0672158B1 Adenovirus with genetic fusion of penton fibre to peptide altering binding specificity |
| 01/17/2001 | EP0626855B1 Health and beauty aid compositions |
| 01/17/2001 | EP0614354B1 Use of salicylic acid for regulating skin atrophy |
| 01/17/2001 | EP0581959B1 Use of macrolide compounds for eye diseases |
| 01/17/2001 | EP0490919B1 Cytoprotective compounds bearing unsaturated hydrocarbon groups having 16 to 20 carbon atoms |
| 01/17/2001 | CN1280619A (Chlamydia trachomatic) genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
| 01/17/2001 | CN1280616A Method and compositions for inducing tumor-specific cytotoxicity |
| 01/17/2001 | CN1280611A Method and compositions for binding hematopoietic stem cells |
| 01/17/2001 | CN1280585A Novel 3.6-hemiketals from the class of 9a-azalides |
| 01/17/2001 | CN1280580A Thienopyrimidine and thienopyridine derivatives useful as anti-cancer agents |
| 01/17/2001 | CN1280579A Novel polymorphic forms of cipamfylline |
| 01/17/2001 | CN1280578A Bis-quaternary ammonium derivatives as neuromuscular relaxants |
| 01/17/2001 | CN1280577A Benzodioxan, benzofuran or benzopyranl derivatives having fundic relaxation properties |
| 01/17/2001 | CN1280575A New tricyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| 01/17/2001 | CN1280572A Inhibiting platelet derivative growth factor and/or quinoline and quinowoline compounds of P56lek tyrosinkinase |
| 01/17/2001 | CN1280570A Substituted fused heterocyclic compounds |
| 01/17/2001 | CN1280568A Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| 01/17/2001 | CN1280561A Amidocarboxylic acid derivatives |
| 01/17/2001 | CN1280560A Adamantane derivatives |
| 01/17/2001 | CN1280559A A noval phosphate salt of isopropyl-methyl-[-2-(3-n-propoxyphenoxy)ethyl] amine |
| 01/17/2001 | CN1280507A Minoxidil-containing liquid preparation composition |
| 01/17/2001 | CN1280506A Oral Preparation |
| 01/17/2001 | CN1280505A Composition for treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant of anti-anxiety drug |
| 01/17/2001 | CN1280503A Method of mobilizing hematopoietic stem cells |
| 01/17/2001 | CN1280499A Use of ginkgo biloba extracts for preparing a medicine |
| 01/17/2001 | CN1280498A Use of phospholipid complexes of extracts of i(vitis vinifera) as anti-atherosclerotic agent |
| 01/17/2001 | CN1280496A Use of brinzolamide to prevent visual field loss |
| 01/17/2001 | CN1280495A Use of a mixture of a diol and an alpha-hydroxy acid for treatment of hyperkeratotic skin diseases |
| 01/17/2001 | CN1280494A Agents for combating neospora spec |
| 01/17/2001 | CN1280493A Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances |
| 01/17/2001 | CN1280492A Porous hydroxyapatite particles as carriers for drug substances |
| 01/17/2001 | CN1280473A Spine distraction implant |
| 01/17/2001 | CN1280463A Smoking products containing antioxidants |
| 01/17/2001 | CN1280126A Substituted pyrazolyl benzene sulfone amides compounds for curing inflammation |
| 01/17/2001 | CN1280125A Substituted pyrazolyl benzene sulfone amides compounds for curing inflammation |
| 01/17/2001 | CN1280008A Strong anti-oxidative composite capsule of grape seed extract OPC and its producing method |
| 01/17/2001 | CN1280006A Medicine ointment prepared with kapur and other Chinese herbal medicine |
| 01/17/2001 | CN1280002A Ointment for curing skin ulcer |
| 01/17/2001 | CN1279992A Medicine for curing and preventing upper respiratory infection and its preparing method |
| 01/17/2001 | CN1279990A Medicine for curing hemiparalysis |
| 01/17/2001 | CN1279975A Medicine for curing stomatocase |
| 01/17/2001 | CN1279966A Chinese medicine composition for curing spur and hyperosteoeny and its preparing method |